Portola Pharmaceuticals, Inc. (PTLA)

34.45
NASDAQ
Prev Close 33.70
Day Low/High 33.40 / 34.55
52 Wk Low/High 14.81 / 45.60
Exchange NASDAQ
Shares Outstanding 66.82B
Market Cap 2.25B
Div & Yield N.A. (N.A)
Tesla, Amazon and Netflix: Doug Kass' Views

Tesla, Amazon and Netflix: Doug Kass' Views

Doug Kass shares his views on why technicals bode ill for tech.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

Portola Pharmaceuticals Enters Into Licensing Agreements For Investigational Agent Andexanet Alfa In Japan Worth Up To $120 Million

Portola Pharmaceuticals Enters Into Licensing Agreements For Investigational Agent Andexanet Alfa In Japan Worth Up To $120 Million

Portola Retains Full Worldwide Commercial Rights to Andexanet Alfa Outside of Japan

Portola Pharmaceuticals To Webcast Corporate Update On January 12, 2016

Portola Pharmaceuticals To Webcast Corporate Update On January 12, 2016

Two Products in Thrombosis Franchise Expected to Launch in Next 18 Months

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

The New England Journal Of Medicine Publishes Results Of Portola Pharmaceuticals' Phase 3 ANNEXA Studies Of Andexanet Alfa

The New England Journal Of Medicine Publishes Results Of Portola Pharmaceuticals' Phase 3 ANNEXA Studies Of Andexanet Alfa

Full Data Set From ANNEXA-R Also Presented Today in Late-Breaking Clinical Trial Session at AHA Scientific Sessions 2015

Portola Pharmaceuticals Announces Phase 3 ANNEXA™-R Part 2 Study Results To Be Presented At American Heart Association Scientific Sessions 2015

Portola Pharmaceuticals Announces Phase 3 ANNEXA™-R Part 2 Study Results To Be Presented At American Heart Association Scientific Sessions 2015

Full Results of Andexanet Alfa and Rivaroxaban Part 2 Study to be Featured in Late-Breaking Clinical Trial Oral Session on November 11th

Portola Pharmaceuticals Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients

Portola Pharmaceuticals Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients

Betrixaban Has Potential to Become First Oral Factor Xa Inhibitor Anticoagulant Approved for Hospital-to-Home Prevention of Venous Thromboembolism in Acute Medically Ill Patients

Portola Pharmaceuticals (PTLA) In A Perilous Reversal

Portola Pharmaceuticals (PTLA) In A Perilous Reversal

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a "perilous reversal" (up big yesterday but down big today) candidate

New Lifetime High For Portola Pharmaceuticals (PTLA)

New Lifetime High For Portola Pharmaceuticals (PTLA)

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a new lifetime high candidate

Portola Pharmaceuticals Announces Second Part Of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa And Rivaroxaban Meets Primary And Secondary Endpoints

Portola Pharmaceuticals Announces Second Part Of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa And Rivaroxaban Meets Primary And Secondary Endpoints

New Topline Data From Pivotal Study Demonstrate Sustained Reversal of Anticoagulant Effect of Factor Xa Inhibitor Rivaroxaban Following Administration of Portola's FDA-Designated Breakthrough Therapy

Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside

Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside

Pharmaceutical stocks were not immune to the recent market selloff, presenting buying opportunities for investors. Here are eight companies with upcoming events to drive their stocks even higher.

TheStreet Quant Rating: D- (Sell)